SEC Form 4 · accession 0001209191-19-019321
Serina Therapeutics, Inc. · SER
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D West
Officer — Chief Executive Officer · Director
Period of report
Mar 11, 2019
Accepted (ET)
Mar 13, 2019 · 9:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001708599
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $4.28 | Mar 11, 2019 | A | 100,000 | A | — | Mar 10, 2029 | Common Stock | 100,000 | 100,000 | D |
| Restricted Stock UnitsF2,F3 | — | Mar 11, 2019 | A | 50,000 | A | — | — | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1One quarter shall vest on March 11, 2020 and the remaining shall vest monthly over 36 months, based upon continuous service.
- F2Grant of restricted stock units under the AgeX 2017 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock.
- F3One quarter of the restricted stock units shall vest upon the completion of 12 months of continuous employment from the date of grant and the balance shall vest in twelve equal quarterly installments upon completion of each quarter of continuous service.